
Dyskinesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Dyskinesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Drugs In Development, 2022, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.
Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyskinesia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 21, 10, 3, 32 and 8 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.
Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Drugs In Development, 2022, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.
Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyskinesia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 21, 10, 3, 32 and 8 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.
Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
206 Pages
- Introduction
- Global Markets Direct Report Coverage
- Dyskinesia – Overview
- Dyskinesia – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Dyskinesia – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Dyskinesia – Companies Involved in Therapeutics Development
- AbbVie Inc
- Addex Therapeutics Ltd
- Adhera Therapeutics Inc
- AEON Biopharma Inc
- AfaSci Inc
- Amarantus Bioscience Holdings Inc
- Astraea Therapeutics LLC
- Bod Australia Ltd
- Cannabis Science Inc
- Celon Pharma SA
- Cerevance Inc
- Cerevel Therapeutics Holdings Inc
- Contera Pharma ApS
- Daewoong Pharmaceutical Co Ltd
- DanPET AB
- Domain Therapeutics SA
- EpiVax Inc
- ES Therapeutics LLC
- GraySpace Therapeutics Inc
- Hua Medicine Shanghai Ltd
- Ipsen SA
- IRLAB Therapeutics AB
- Jazz Pharmaceuticals Plc
- Junaxo Inc
- Luye Pharma Group Ltd
- MapLight therapeutics Inc
- Merz Pharma GmbH & Co KgaA
- MitoDys Therapeutics Ltd
- Molomics Biotech SL
- Motac Neuroscience Ltd
- Neuralina Therapeutics Inc
- Neurim Pharmaceuticals Ltd
- Neurocea Pharmaceuticals
- Neurocrine Biosciences Inc
- Neurolixis Inc
- Newron Pharmaceuticals SpA
- Nine Square Therapeutics Inc
- Nissan Chemical Corp
- Novartis AG
- OB Pharmaceuticals
- Peptron Inc
- PharmaTher Holdings Ltd
- PolyCore Therapeutics LLC
- Praxis Precision Medicines Inc
- Puretech Health Plc
- Revance Therapeutics Inc
- Sage Therapeutics Inc
- SalubRx Therapeutics Inc
- Shionogi & Co Ltd
- Sinopia Biosciences Inc
- SOM Biotech SL
- Sumitomo Pharma Co Ltd
- Tempero Bio
- Teva Pharmaceutical Industries Ltd
- Trevi Therapeutics Inc
- Ultragenyx Pharmaceutical Inc
- VistaGen Therapeutics Inc
- Dyskinesia – Drug Profiles
- (cannabidiol + dronabinol) – Drug Profile
- abobotulinumtoxina – Drug Profile
- ABP-450 – Drug Profile
- AFA-101 – Drug Profile
- AFA-279 – Drug Profile
- AT-403 – Drug Profile
- AV-101 – Drug Profile
- befiradol – Drug Profile
- bevantolol – Drug Profile
- brexanolone – Drug Profile
- cannabidiol – Drug Profile
- CBISOBLD-001 – Drug Profile
- CP-011 – Drug Profile
- CPL-500036 – Drug Profile
- CVN-417 – Drug Profile
- cycloserine – Drug Profile
- deutetrabenazine – Drug Profile
- dipraglurant – Drug Profile
- dipraglurant ER – Drug Profile
- dipraglurant IR – Drug Profile
- Drugs for Drug-Induced Dyskinesia – Drug Profile
- Drugs for Dyskinesia – Drug Profile
- Drugs for Tardive Dyskinesia – Drug Profile
- DSP-9632P – Drug Profile
- DSR-143136 – Drug Profile
- DT-095435 – Drug Profile
- eltoprazine – Drug Profile
- ES-481 – Drug Profile
- HTL-0014242 – Drug Profile
- incobotulinumtoxin A – Drug Profile
- JM-010 – Drug Profile
- ketamine – Drug Profile
- Lead Optimization – Drug Profile
- LPM-3770164 SR – Drug Profile
- LY-03015 – Drug Profile
- mesdopetam – Drug Profile
- mesocarb – Drug Profile
- mGLUR5 NAM – Drug Profile
- ML-007 – Drug Profile
- ML-009 – Drug Profile
- NA-100 – Drug Profile
- NA-200 – Drug Profile
- NA-300 – Drug Profile
- nalbuphine hydrochloride ER – Drug Profile
- NBI-827104 – Drug Profile
- Neu-240 – Drug Profile
- nicotine bitartrate – Drug Profile
- NIP-301 – Drug Profile
- NS-10712 – Drug Profile
- onabotulinumtoxin A – Drug Profile
- onabotulinumtoxinA – Drug Profile
- onabotulinumtoxinA biosimilar – Drug Profile
- PCT-3012 – Drug Profile
- PPI-1011 – Drug Profile
- prabotulinumtoxin A biosimilar – Drug Profile
- PRAX-114 – Drug Profile
- PRAX-944 – Drug Profile
- PT-001 – Drug Profile
- PT-320 – Drug Profile
- rimtuzalcap – Drug Profile
- RNAi Gene Therapy to Inhibit NURR1 for Dyskinesia – Drug Profile
- RT-002 – Drug Profile
- S-109802 – Drug Profile
- safinamide mesylate – Drug Profile
- SAGE-324 – Drug Profile
- SB-0107 – Drug Profile
- SBX-413 – Drug Profile
- SBX-677 – Drug Profile
- SBX-774 – Drug Profile
- SK-609 – Drug Profile
- Small Molecule to Target Ion Channels for CNS Disorders – Drug Profile
- Small Molecules for Drug-Induced Dyskinesia – Drug Profile
- Small Molecules for L-dopa Induced Dyskinesia and Psychosis – Drug Profile
- Small Molecules for Neurodegenerative Disease – Drug Profile
- Small Molecules to Activate PRKN for Parkinson's Disease and Drug-Induced Dyskinesia – Drug Profile
- Small Molecules to Antagonize GPCR for Central Nervous System Diseases – Drug Profile
- Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia – Drug Profile
- Small Molecules to Antagonize Mu Opiate Receptor for Dyskinesia – Drug Profile
- Small-Molecule Therapeutics – Drug Profile
- SOM-3366 – Drug Profile
- suvecaltamide hydrochloride – Drug Profile
- suvecaltamide hydrochloride MR – Drug Profile
- TD-567 – Drug Profile
- triheptanoin – Drug Profile
- valbenazine tosylate – Drug Profile
- Dyskinesia – Dormant Projects
- Dyskinesia – Discontinued Products
- Dyskinesia – Product Development Milestones
- Featured News & Press Releases
- May 09, 2022: Praxis Precision Medicines reports positive topline results from PRAX-944 Phase 2a study in essential tremor patients
- May 02, 2022: Teva announces settlement with Lupin resolving AUSTEDO (deutetrabenazine) patent dispute
- Apr 11, 2022: AEON Biopharma completes enrollment in phase 2 clinical study of ABP-450 in cervical dystonia
- Apr 01, 2022: Neurocrine Biosciences presents phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022
- Apr 01, 2022: Praxis Precision Medicines to present data from PRAX-944 for Essential Tremor at 2022 American Academy of Neurology Annual Meeting
- Mar 28, 2022: Revance to present new clinical data on DaxibotulinumtoxinA for injection from the ASPEN phase 3 program at the 2022 American Academy of Neurology Annual Meeting
- Mar 28, 2022: Regulatory approval of DYSVAL capsules 40mg for treatment of tardive dyskinesia in Japan
- Mar 24, 2022: Neurocrine Biosciences to present data from INGREZZA at the American Academy of Neurology 2022 in-person and virtual annual meeting
- Mar 23, 2022: PharmaTher announces positive topline results from clinical study of Ketamine for Parkinson’s Disease
- Feb 04, 2022: MapLight Therapeutics announces initiation of phase 1 clinical trial for novel therapy to treat patients with schizophrenia or dyskinesias
- Dec 15, 2021: Jazz Pharmaceuticals announces first patient enrolled in phase 2b clinical trial evaluating novel Suvecaltamide (JZP385) for once-daily treatment of adults with essential tremor
- Dec 07, 2021: PureTech advances wholly-owned candidate LYT-300 (oral allopregnanolone) into clinical study for potential treatment of neurological and neuropsychological conditions
- Nov 22, 2021: Adhera Therapeutics receives notice of allowance for new Canadian Patent Covering MLR-1019 for dyskinesia and related disorders
- Nov 02, 2021: The results of CPL’36 – PDE10a inhibitor to be presented in the poster session at Neuroscience 2021.
- Nov 01, 2021: Neurocrine Biosciences presents new INGREZZA (valbenazine) data at Psych Congress 2021
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Dyskinesia, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Universities/Institutes, 2022
- Table 6: Products under Development by Companies, 2022
- Table 7: Products under Development by Companies, 2022 (Contd..1)
- Table 8: Products under Development by Companies, 2022 (Contd..2)
- Table 9: Products under Development by Companies, 2022 (Contd..3)
- Table 10: Products under Development by Companies, 2022 (Contd..4)
- Table 11: Products under Development by Universities/Institutes, 2022
- Table 12: Number of Products by Stage and Target, 2022
- Table 13: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 14: Number of Products by Stage and Mechanism of Action, 2022
- Table 15: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 16: Number of Products by Stage and Route of Administration, 2022
- Table 17: Number of Products by Stage and Molecule Type, 2022
- Table 18: Dyskinesia – Pipeline by AbbVie Inc, 2022
- Table 19: Dyskinesia – Pipeline by Addex Therapeutics Ltd, 2022
- Table 20: Dyskinesia – Pipeline by Adhera Therapeutics Inc, 2022
- Table 21: Dyskinesia – Pipeline by AEON Biopharma Inc, 2022
- Table 22: Dyskinesia – Pipeline by AfaSci Inc, 2022
- Table 23: Dyskinesia – Pipeline by Amarantus Bioscience Holdings Inc, 2022
- Table 24: Dyskinesia – Pipeline by Astraea Therapeutics LLC, 2022
- Table 25: Dyskinesia – Pipeline by Bod Australia Ltd, 2022
- Table 26: Dyskinesia – Pipeline by Cannabis Science Inc, 2022
- Table 27: Dyskinesia – Pipeline by Celon Pharma SA, 2022
- Table 28: Dyskinesia – Pipeline by Cerevance Inc, 2022
- Table 29: Dyskinesia – Pipeline by Cerevel Therapeutics Holdings Inc, 2022
- Table 30: Dyskinesia – Pipeline by Contera Pharma ApS, 2022
- Table 31: Dyskinesia – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
- Table 32: Dyskinesia – Pipeline by DanPET AB, 2022
- Table 33: Dyskinesia – Pipeline by Domain Therapeutics SA, 2022
- Table 34: Dyskinesia – Pipeline by EpiVax Inc, 2022
- Table 35: Dyskinesia – Pipeline by ES Therapeutics LLC, 2022
- Table 36: Dyskinesia – Pipeline by GraySpace Therapeutics Inc, 2022
- Table 37: Dyskinesia – Pipeline by Hua Medicine Shanghai Ltd, 2022
- Table 38: Dyskinesia – Pipeline by Ipsen SA, 2022
- Table 39: Dyskinesia – Pipeline by IRLAB Therapeutics AB, 2022
- Table 40: Dyskinesia – Pipeline by Jazz Pharmaceuticals Plc, 2022
- Table 41: Dyskinesia – Pipeline by Junaxo Inc, 2022
- Table 42: Dyskinesia – Pipeline by Luye Pharma Group Ltd, 2022
- Table 43: Dyskinesia – Pipeline by MapLight therapeutics Inc, 2022
- Table 44: Dyskinesia – Pipeline by Merz Pharma GmbH & Co KgaA, 2022
- Table 45: Dyskinesia – Pipeline by MitoDys Therapeutics Ltd, 2022
- Table 46: Dyskinesia – Pipeline by Molomics Biotech SL, 2022
- Table 47: Dyskinesia – Pipeline by Motac Neuroscience Ltd, 2022
- Table 48: Dyskinesia – Pipeline by Neuralina Therapeutics Inc, 2022
- Table 49: Dyskinesia – Pipeline by Neurim Pharmaceuticals Ltd, 2022
- Table 50: Dyskinesia – Pipeline by Neurocea Pharmaceuticals, 2022
- Table 51: Dyskinesia – Pipeline by Neurocrine Biosciences Inc, 2022
- Table 52: Dyskinesia – Pipeline by Neurolixis Inc, 2022
- Table 53: Dyskinesia – Pipeline by Newron Pharmaceuticals SpA, 2022
- Table 54: Dyskinesia – Pipeline by Nine Square Therapeutics Inc, 2022
- Table 55: Dyskinesia – Pipeline by Nissan Chemical Corp, 2022
- Table 56: Dyskinesia – Pipeline by Novartis AG, 2022
- Table 57: Dyskinesia – Pipeline by OB Pharmaceuticals, 2022
- Table 58: Dyskinesia – Pipeline by Peptron Inc, 2022
- Table 59: Dyskinesia – Pipeline by PharmaTher Holdings Ltd, 2022
- Table 60: Dyskinesia – Pipeline by PolyCore Therapeutics LLC, 2022
- Table 61: Dyskinesia – Pipeline by Praxis Precision Medicines Inc, 2022
- Table 62: Dyskinesia – Pipeline by Puretech Health Plc, 2022
- Table 63: Dyskinesia – Pipeline by Revance Therapeutics Inc, 2022
- Table 64: Dyskinesia – Pipeline by Sage Therapeutics Inc, 2022
- Table 65: Dyskinesia – Pipeline by SalubRx Therapeutics Inc, 2022
- Table 66: Dyskinesia – Pipeline by Shionogi & Co Ltd, 2022
- Table 67: Dyskinesia – Pipeline by Sinopia Biosciences Inc, 2022
- Table 68: Dyskinesia – Pipeline by SOM Biotech SL, 2022
- Table 69: Dyskinesia – Pipeline by Sumitomo Pharma Co Ltd, 2022
- Table 70: Dyskinesia – Pipeline by Tempero Bio, 2022
- Table 71: Dyskinesia – Pipeline by Teva Pharmaceutical Industries Ltd, 2022
- Table 72: Dyskinesia – Pipeline by Trevi Therapeutics Inc, 2022
- Table 73: Dyskinesia – Pipeline by Ultragenyx Pharmaceutical Inc, 2022
- Table 74: Dyskinesia – Pipeline by VistaGen Therapeutics Inc, 2022
- Table 75: Dyskinesia – Dormant Projects, 2022
- Table 76: Dyskinesia – Dormant Projects, 2022 (Contd..1)
- Table 77: Dyskinesia – Dormant Projects, 2022 (Contd..2)
- Table 78: Dyskinesia – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Dyskinesia, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 10: Number of Products by Molecule Types, 2022
- Figure 11: Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.